Bioinformatics and variability in drug response: a protein structural perspective

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Journal of the Royal Society Interface

• Publication date

  2012-07-07

• Fields of study

  Biology, Medicine, Computer Science

• Identifiers
  DOI 10.1098/rsif.2011.0843PMID 22552919PMCID PMC3367825
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer systems biology.

  2016cited by this paper
• ModBase, a database of annotated comparative protein structure models and associated resources

  2013cited by this paper
• A multivariate model of ErbB network composition predicts ovarian cancer cell response to canertinib

  2012cited by this paper
• PharmGKB summary: very important pharmacogene information for CYP1A2

  2012cited by this paper
• Bioinformatics for personal genome interpretation

  2012cited by this paper
• Ab initio protein structure assembly using continuous structure fragments and optimized knowledge‐based force field

  2012cited by this paper
• Predictions

  2012cited by this paper
• Investigation by site‐directed mutagenesis of the role of cytochrome P450 2B4 non‐active‐site residues in protein–ligand interactions based on crystal structures of the ligand‐bound enzyme

  2012cited by this paper
• A Role for Both Conformational Selection and Induced Fit in Ligand Binding by the LAO Protein

  2011cited by this paper
• CASP9 assessment of free modeling target predictions

  2011cited by this paper
• Drug discovery and the human kinome: recent trends.

  2011cited by this paper
• Challenges for the prediction of macromolecular interactions.

  2011cited by this paper
• Exciting Times beyond the Brain: Metabotropic Glutamate Receptors in Peripheral and Non-Neural Tissues

  2011cited by this paper
• Drug Safety Sciences and the Bottleneck in Drug Development

  2011cited by this paper
• Biomolecular modeling and simulation: a field coming of age

  2011cited by this paper
• sc-PDB: a database for identifying variations and multiplicity of 'druggable' binding sites in proteins

  2011cited by this paper
• Genetics and variable drug response.

  2011cited by this paper
• Targeting FKBP isoforms with small-molecule ligands.

  2011cited by this paper
• Challenges and advances in computational docking: 2009 in review

  2011cited by this paper
• Prediction of ligand‐binding sites of proteins by molecular docking calculation for a random ligand library

  2011cited by this paper
• Old friends in new guise: repositioning of known drugs with structural bioinformatics

  2011cited by this paper
• Turning a protein kinase on or off from a single allosteric site via disulfide trapping

  2011cited by this paper
• Using Multiple Microenvironments to Find Similar Ligand-Binding Sites: Application to Kinase Inhibitor Binding

  2011cited by this paper
• An allosteric inhibitor of the human Cdc34 ubiquitin-conjugating enzyme.

  2011cited by this paper
• The G protein-coupled receptors in the pufferfish Takifugu rubripes

  2011cited by this paper
• Genotype and SNP calling from next-generation sequencing data

  2011cited by this paper
• Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database

  2011cited by this paper
• Long-Range Effects of a Peripheral Mutation on the Enzymatic Activity of Cytochrome P450 1A2

  2011cited by this paper
• Mechanism of the hydrophobic effect in the biomolecular recognition of arylsulfonamides by carbonic anhydrase

  2011cited by this paper
• Structure-based drug discovery and protein targets in the CNS.

  2011cited by this paper
• Structure-based drug design to augment hit discovery.

  2011cited by this paper
• Conformational control inhibition of the BCR-ABL1 tyrosine kinase, including the gatekeeper T315I mutant, by the switch-control inhibitor DCC-2036.

  2011cited by this paper
• In silico repositioning of approved drugs for rare and neglected diseases.

  2011cited by this paper
• Structure-based druggability assessment--identifying suitable targets for small molecule therapeutics.

  2011cited by this paper
• Selectivity filters to edit out deleterious side effects in kinase inhibitors.

  2011cited by this paper
• Optimized torsion-angle normal modes reproduce conformational changes more accurately than cartesian modes.

  2011cited by this paper
• Bridging the efficacy–effectiveness gap: a regulator's perspective on addressing variability of drug response

  2011cited by this paper
• A novel mutation of the PTCH1 gene activates the Shh/Gli signaling pathway in a Chinese family with nevoid basal cell carcinoma syndrome.

  2011cited by this paper
• Automated protein structure modeling in CASP9 by I‐TASSER pipeline combined with QUARK‐based ab initio folding and FG‐MD‐based structure refinement

  2011cited by this paper
• Definition of the hydrogen bond (IUPAC Recommendations 2011)

  2011cited by this paper
• Structural Mechanism of the Pan‐BCR‐ABL Inhibitor Ponatinib (AP24534): Lessons for Overcoming Kinase Inhibitor Resistance

  2011cited by this paper
• Unexpected active-site flexibility in the structure of human neutrophil elastase in complex with a new dihydropyrimidone inhibitor.

  2011cited by this paper
• Improving protein structure prediction using multiple sequence-based contact predictions.

  2011cited by this paper
• The productivity crisis in pharmaceutical R&D

  2011cited by this paper
• Flexibility of human cytochrome P450 enzymes: molecular dynamics and spectroscopy reveal important function-related variations.

  2011cited by this paper
• Searching the protein structure database for ligand-binding site similarities using CPASS v.2

  2011cited by this paper
• A new disease-specific machine learning approach for the prediction of cancer-causing missense variants.

  2011cited by this paper
• How does a drug molecule find its target binding site?

  2011cited by this paper
• Identify drug repurposing candidates by mining the Protein Data Bank

  2011cited by this paper
• Overcoming the drug resistance problem with second-generation tyrosine kinase inhibitors: from enzymology to structural models.

  2011cited by this paper
• Trends in the exploitation of novel drug targets

  2011cited by this paper
• Recent advances in the therapeutic perspectives of Nutlin-3.

  2011cited by this paper
• Let’s get honest about sampling

  2011cited by this paper
• Protein flexibility and ligand recognition: challenges for molecular modeling.

  2011cited by this paper
• CASP9 results compared to those of previous casp experiments

  2011cited by this paper
• Assessment of template based protein structure predictions in CASP9

  2011cited by this paper
• Bioinformatics challenges for personalized medicine

  2011cited by this paper
• Probing the links between in vitro potency, ADMET and physicochemical parameters

  2011cited by this paper
• How were new medicines discovered?

  2011cited by this paper
• Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development.

  2011cited by this paper
• Improving the prediction of disease-related variants using protein three-dimensional structure

  2011cited by this paper
• The structural basis of agonist-induced activation in constitutively active rhodopsin

  2011cited by this paper
• Pharmacogenetic mechanisms underlying unanticipated drug responses.

  2011cited by this paper
• Comparative modeling: the state of the art and protein drug target structure prediction.

  2011cited by this paper
• The Structural Biology Knowledgebase: a portal to protein structures, sequences, functions, and methods

  2011cited by this paper
• In Silico Elucidation of the Recognition Dynamics of Ubiquitin

  2011cited by this paper
• A new face and new challenges for Online Mendelian Inheritance in Man (OMIM®)

  2011cited by this paper
• PharmGKB summary: cytochrome P450, family 2, subfamily J, polypeptide 2: CYP2J2.

  2011cited by this paper
• Remote thioredoxin recognition using evolutionary conservation and structural dynamics.

  2011cited by this paper
• Beyond structural genomics: computational approaches for the identification of ligand binding sites in protein structures

  2011cited by this paper
• Analysis of in vitro bioactivity data extracted from drug discovery literature and patents: Ranking 1654 human protein targets by assayed compounds and molecular scaffolds

  2011cited by this paper
• Phased Whole-Genome Genetic Risk in a Family Quartet Using a Major Allele Reference Sequence

  2011cited by this paper
• Optimization of warfarin dose by population-specific pharmacogenomic algorithm

  2011cited by this paper
• Selective inhibition of BET bromodomains

  2010cited by this paper
• A machine learning approach to predicting protein-ligand binding affinity with applications to molecular docking

  2010cited by this paper
• Structural genomics-impact on biomedicine and drug discovery.

  2010cited by this paper
• Validation and comparison of pharmacogenetics-based warfarin dosing algorithms for application of pharmacogenetic testing.

  2010cited by this paper
• A map of human genome variation from population-scale sequencing

  2010cited by this paper
• The structural basis for agonist and partial agonist action on a β1-adrenergic receptor

  2010cited by this paper
• Structures of human carbonic anhydrase II/inhibitor complexes reveal a second binding site for steroidal and nonsteroidal inhibitors.

  2010cited by this paper
• MK-2461, a novel multitargeted kinase inhibitor, preferentially inhibits the activated c-Met receptor.

  2010cited by this paper
• Atomic-Level Characterization of the Structural Dynamics of Proteins

  2010cited by this paper
• Activity of the Aurora Kinase Inhibitor VX-680 against Bcr/Abl-Positive Acute Lymphoblastic Leukemias

  2010cited by this paper
• Pharmacogenomics and bioinformatics: PharmGKB.

  2010cited by this paper
• Molecular Dynamics Simulations Show That Conformational Selection Governs the Binding Preferences of Imatinib for Several Tyrosine Kinases*

  2010cited by this paper
• Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.

  2010cited by this paper
• Network medicine: a network-based approach to human disease

  2010cited by this paper
• Analyzing the Topology of Active Sites: On the Prediction of Pockets and Subpockets

  2010cited by this paper
• Docking Studies on Isoform-Specific Inhibition of Phosphoinositide-3-Kinases

  2010cited by this paper
• The HADDOCK web server for data-driven biomolecular docking

  2010cited by this paper
• Exploring the cause of drug resistance by the detrimental missense mutations in KIT receptor: computational approach

  2010cited by this paper
• Computational approaches for protein function prediction: a combined strategy from multiple sequence alignment to molecular docking-based virtual screening.

  2010cited by this paper
• Crystal Structure of a Cytochrome P450 2B6 Genetic Variant in Complex with the Inhibitor 4-(4-Chlorophenyl)imidazole at 2.0-Å Resolution

  2010cited by this paper
• Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant.

  2010cited by this paper
• VnD: a structure-centric database of disease-related SNPs and drugs

  2010cited by this paper
• Applications of current proteomics techniques in modern drug design.

  2010cited by this paper
• Effects of the V82A and I54V mutations on the dynamics and ligand binding properties of HIV-1 protease

  2010cited by this paper
• Molecular shape technologies in drug discovery: methods and applications.

  2010cited by this paper
• In-Silico Approaches to Multi-target Drug Discovery

  2010cited by this paper
• ConSurf 2010: calculating evolutionary conservation in sequence and structure of proteins and nucleic acids

  2010cited by this paper

• Structural modeling and machine learning-enhanced QSPR analysis of CAD-related and cardiovascular therapy drugs using topological descriptors

  2026cites this paper
• Why different PDB IDs for the same dysregulated protein can lead to inconsistent in-silico predictions and preclinical results

  2025cites this paper
• Artificial intelligence in metalloprotein binding site prediction: A systematic review bridging bioinformatics and biotechnology.

  2025cites this paper
• GastroDL-Fusion: A Dual-Modal Deep Learning Framework Integrating Protein-Ligand Complexes and Gene Sequences for Gastrointestinal Disease Drug Discovery

  2025cites this paper
• MPLBind: Predicting the Effect of Binding Site Point Mutations on Protein-Ligand Binding Affinity Using Protein Large Language Models

  2025cites this paper
• Computational investigation of stigmasterol as a potential therapeutic agent for cervical cancer: insights from density functional theory (DFT) and molecular docking studies

  2025cites this paper
• A comprehensive machine learning for high throughput Tuberculosis sequence analysis, functional annotation, and visualization

  2025cites this paper
• Genomic signatures of selection in drug metabolizing genes across cattle populations

  2025cites this paper
• Engineering local Kenyan Irish potato varieties as carriers for edible cholera vaccines

  2025cites this paper
• Machine Learning for Multi-Target Drug Discovery: Challenges and Opportunities in Systems Pharmacology

  2025cites this paper
• Effects of genetic variation on the structure of RNA and protein

  2024cites this paper
• High throughput biological sequence analysis using machine learning-based integrative pipeline for extracting functional annotation and visualization

  2024cites this paper
• Fritillaria steroidal alkaloids and their multi-target therapeutic mechanisms: insights from network pharmacology

  2024cites this paper
• PSnpBind-ML: predicting the effect of binding site mutations on protein-ligand binding affinity

  2023cites this paper
• SiteRadar: Utilizing Graph Machine Learning for Precise Mapping of Protein-Ligand-Binding Sites

  2023cites this paper
• A pixel-enhanced deep convolutional neural network for classifying immunohistochemistry images

  2023cites this paper
• Molecular modelling, docking and network analysis of phytochemicals from Haritaki churna: role of protein cross-talks for their action

  2023cites this paper
• Structural and Phylogenetic Analysis of CXCR4 Protein Reveals New Insights into Its Role in Emerging and Re-Emerging Diseases in Mammals

  2023cites this paper
• First report of computational protein–ligand docking to evaluate susceptibility to HIV integrase inhibitors in HIV-infected Iranian patients

  2022cites this paper
• In silico analyses of acetylcholinesterase (AChE) and its genetic variants in interaction with the anti‐Alzheimer drug Rivastigmine

  2022cites this paper
• Analysis of the Biochemical Reaction Status by Real-Time Monitoring Molecular Diffusion Behaviors Using a Transistor Biosensor Integrated with a Microfluidic Channel

  2021cites this paper
• Opposite genotype-specific effects of serotoninergic treatments on Pavlovian Conditioned Approach in mice of two inbred strains C57 BL/6J and DBA/2J

  2021cites this paper
• Incorporating label correlations into deep neural networks to classify protein subcellular location patterns in immunohistochemistry images

  2021cites this paper
• Global spectrum of population‐specific common missense variation in cytochrome P450 pharmacogenes

  2021cites this paper
• Characterizations of protein-ligand reaction kinetics by transistor-microfluidic integrated sensors.

  2020cites this paper
• Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors

  2020cites this paper
• Synthesis, DNA/RNA-interaction and biological activity of benzo[k,l]xanthene lignans.

  2020cites this paper
• Molecular Dynamics Simulations in Drug Discovery

  2019cites this paper
• Peptide/Receptor Co-evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21

  2019cites this paper
• Peptide/Receptor Evolution Explains the Lipolytic Function of the Neuropeptide TLQP-21

  2019cites this paper
• Pharmacophore-based Screening of Antimycobacterial 2-Pyrone-Tethered Nitrobenzothiazinone

  2019cites this paper
• Systems Chemical Biology

  2019cites this paper
• Pharmacogenes (PGx-genes): Current understanding and future directions.

  2019cites this paper
• Vitamin D receptor (VDR) non-synonymous single nucleotide polymorphisms (nsSNPs) affect the calcitriol drug response - A theoretical insight.

  2018cites this paper
• In Silico Target Prediction for Small Molecules.

  2018cites this paper
• Simultaneous Binding of Folic Acid and Methotrexate to Human Serum Albumin: Insights into the Structural Changes of Protein and the Location and Competitive Displacement of Drugs

  2018cites this paper
• Alanine mutation of the catalytic sites of Pantothenate Synthetase causes distinct conformational changes in the ATP binding region

  2018cites this paper
• In silico locating the immune-reactive segments of Lepidium draba peroxidase and designing a less immune-reactive enzyme derivative

  2017cites this paper
• On the importance of composite protein multiple ligand interactions in protein pockets

  2017cites this paper
• The impact of structural biology in medicine illustrated with four case studies

  2017cites this paper
• Double Mutants in DNA Gyrase Lead to Ofloxacin Resistance in Mycobacterium tuberculosis

  2017cites this paper
• Identification of novel allosteric inhibitors of mutant isocitrate dehydrogenase 1 by cross docking-based virtual screening.

  2017cites this paper
• Sarcocystis neurona Protein Kinases: Computational Identification, Evolutionary Analysis and Putative Inhibitor Docking

  2017cites this paper
• Patient‐Level Adverse Event Patterns in a Single‐Institution Study of the Multi‐Kinase Inhibitor Sorafenib

  2016cites this paper
• Molecular principles behind pyrazinamide resistance due to mutations in panD gene in Mycobacterium tuberculosis.

  2016cites this paper
• Polymorphism in ion channel genes of Dirofilaria immitis: Relevant knowledge for future anthelmintic drug design

  2016cites this paper
• Untapped Potential of Disordered Proteins in Current Druggable Human Proteome.

  2016cites this paper
• Structural difficulty index: a reliable measure for modelability of protein tertiary structures.

  2016cites this paper
• Drugging Membrane Protein Interactions.

  2016cites this paper
• Combining bioinformatics, chemoinformatics and experimental approaches to design chemical probes: Applications in the field of blood coagulation.

  2016cites this paper
• Analysis of the Applicability and Use of Lipinski`s Rule for Central Nervous System Drugs

  2016cites this paper
• 개인 유전체의 유전변이정보를 이용한 생리활성변이 분석 시스템

  2016cites this paper
• Design Strategies, Structures and Molecular Interactions of Small Molecule Src Inhibitors.

  2016cites this paper
• Hum‐mPLoc 3.0: prediction enhancement of human protein subcellular localization through modeling the hidden correlations of gene ontology and functional domain features

  2016cites this paper
• Parsing interindividual drug variability: an emerging role for systems pharmacology

  2015cites this paper
• Rational RNA Riboswitch Design through a Massive Open Laboratory

  2015cites this paper
• In silico design of low molecular weight protein-protein interaction inhibitors: Overall concept and recent advances.

  2015cites this paper
• In Silico Protein-Protein Interactions: Avoiding Data and Method Biases Over Sensitivity and Specificity.

  2015cites this paper
• Recent progress on structural bioinformatics research of cytochrome P450 and its impact on drug discovery.

  2015cites this paper
• Low-Quality Structural and Interaction Data Improves Binding Affinity Prediction via Random Forest

  2015cites this paper
• In silico analysis and molecular modeling of RNA polymerase, sigma S (RpoS) protein in Pseudomonas aeruginosa PAO1.

  2015cites this paper
• Improving AutoDock Vina Using Random Forest: The Growing Accuracy of Binding Affinity Prediction by the Effective Exploitation of Larger Data Sets

  2015cites this paper
• INPS: predicting the impact of non-synonymous variations on protein stability from sequence

  2015cites this paper
• Evolutionary Diagnosis of non-synonymous variants involved in differential drug response

  2015cites this paper
• Computational drug design strategies applied to the modelling of human immunodeficiency virus-1 reverse transcriptase inhibitors

  2015cites this paper
• Personalized Biochemistry and Biophysics

  2015cites this paper
• Computational methods and resources for the interpretation of genomic variants in cancer

  2015cites this paper
• Machine‐learning scoring functions to improve structure‐based binding affinity prediction and virtual screening

  2015cites this paper
• DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach

  2014cites this paper
• Computer-Aided Targeting of the PI3K/Akt/mTOR Pathway: Toxicity Reduction and Therapeutic Opportunities

  2014cites this paper
• In pursuit of an inhibitory drug for the proton channel

  2014cites this paper
• Computational approaches and resources in single amino acid substitutions analysis toward clinical research.

  2014cites this paper
• Structural bioinformatics of the interactome.

  2014cites this paper
• Integrating In Silico Prediction Methods, Molecular Docking, and Molecular Dynamics Simulation to Predict the Impact of ALK Missense Mutations in Structural Perspective

  2014cites this paper
• In silico comparative characterization of pharmacogenomic missense variants

  2014cites this paper
• Does a More Precise Chemical Description of Protein–Ligand Complexes Lead to More Accurate Prediction of Binding Affinity?

  2014cites this paper
• Efficient Methods for the Quantum Chemical Treatment of Protein Structures: The Effects of London-Dispersion and Basis-Set Incompleteness on Peptide and Water-Cluster Geometries.

  2013cites this paper
• Structural systems pharmacology: the role of 3D structures in next-generation drug development.

  2013cites this paper
• Computational and theoretical methods for protein folding.

  2013cites this paper
• Computational medicinal chemistry for rational drug design: Identification of novel chemical structures with potential anti-tuberculosis activity.

  2013cites this paper
• Antibacterial mechanisms identified through structural systems pharmacology

  2013cites this paper
• Comparative modeling and structure prediction: application to drug discovery

  2013cites this paper
• CEP proteins: the knights of centrosome dynasty

  2013cites this paper
• Insight into Nek2A activity regulation and its pharmacological prospects

  2013influential citation
• Rational Prediction with Molecular Dynamics for Hit Identification

  2012cites this paper